MyBaby, the world’s first blockchain-based IVF service app, built by VeChain in conjunction with DNV, an international accredited registrar and classification society, was featured on a Chinese state-owned TV channel, STV.
The new development was shared moments ago via the official Twitter handle of the VeChain Foundation. According to the report, the official launch of MyBaby was attended by government officials, indicating the importance of the App to society and the world at large.
Captioning the clip of the report, VeChain Foundation tweeted, “VeChain & DNV’s ‘MyBaby’ was featured on Chinese state-owned TV channel, STV! With the official launch attended by gov officials, we gained mainstream recognition just a day after launch! VET continues to lead. Subbed ver. to come later.”
VeChain & DNV’s ‘MyBaby’ was featured on Chinese state-owned TV channel, STV!
— VeChain Foundation (@vechainofficial) June 3, 2021
The Purpose of MyBaby, Blockchain-Based IVF Service App
As aforementioned, VeChain, the leading enterprise blockchain platform, partnered with DNV to build MyBaby, the blockchain-based IVF service app.
According to the report, MyBaby is designed to improve the IVF process from data management to providing families with the ability to track the development of their baby.
It’s specifically made for Renji Hospital, a top-ranking China-based hospital affiliated with the Shanghai Jiaotong University School of Medicine.
Going by the report, MyBaby will combine the merits of third-party assured data verification with the immutability of blockchain technology.
How MyBaby will leverage VeChain blockchain reads in part as follows:
“All information, imagery and data trails, from imagery produced by medical tools to the delivery of the zygote itself will be securely uploaded on VeChainThor blockchain and is only accessible to authorized users of the MyBaby Application…”
“The cryptographically secured properties of blockchain technology create a secure and reliable environment and enhance the user experience in a way that is unprecedented in the IVF field.”